Bharat Biotech has applied for the third dose clinical trial
According to the data of the Union Health Ministry, 6,563 new cases of corona have been reported in the country in the last 24 hours. With this, the total number of COVID-19 cases in India has increased to 3,47,46,838, while active cases have decreased. 82,267, which is the lowest in 572 days. At the same time, its new variant Omicron is also starting to scare. So far 161 cases of Omicron have been reported in the country. Booster dose is being discussed continuously to curb the corona virus. Amidst all this, Bharat Biotech has submitted an application for the third phase of clinical trial for the third dose of its vaccine in the country.
Clinical trial for “booster dosage purpose”
According to sources, Bharat Biotech had submitted an application for the third dose of its intranasal COVID vaccine on 15 December. This is a clinical trial of the “intranasal” vaccine of Covaxin. But this time it is for booster or third dose purposes. A separate trial of an intranasal vaccine is already in its final stages.
Intranasal vaccines have the ability to prevent transmission, according to Bharat Biotech.
Val of Covaxin is Stable for 28 Days at 2 to 8°C: Opened vial of Covaxin may be stored at 2-8°C for up to 28 days and discarded immediately after one day or at the end of vaccination session There is no need to give.
20 Dose Vial: We believe in doing our part to care for our environment, Multi Dose Vial Policy saves money for procurement agencies by reducing cold chain logistics and management, reducing carbon footprint, open vial waste Reduced costs related to cold chain distribution, cold chain storage, biomedical waste disposal etc.
Eco Friendly: Most importantly, we believe in being eco-friendly by reducing the amount of packing material and single-use plastic used in vaccine manufacturing, storage, distribution and disposal.
Shelf Life of Covaxin Up to 12 Months: Covaxin has been approved for use by the Drugs Controller General of India and WHO Emergency Use Listing (WHO EUL) under a 28-day multi-dose viol policy. CDSCO has recently approved the extension of Covaccine shelf life by 12 months from the date of manufacture.”
Serum Institute had collected data on booster doseSerum Institute had collected data on booster dose
Let us inform that Serum Institute of India has recently submitted data regarding booster dosage to the Subject Expert Committee (SEC). However, the Subject Expert Committee did not agree with the UK’s Medicines and Healthcare products Regulatory Agency’s decision to allow booster doses.
Biological E introduced Phase 3 clinical trial
The Subject Expert Committee has asked Serum to come up with such a proposal regarding the booster dose, so that it can be proved that there is a need for a booster dose in India. At the same time, the Subject Expert Committee has given this order to all the vaccine makers. Recently, Biological E presented a clinical trial of Phase 3 again regarding the vaccine. In which there was talk about booster dose. The third phase trial of Biological E is currently completed. But this company of vaccination has not been approved yet.
